Peanut Allergy Immunotherapy Options Oral Immunotherapy PatientDisease Characteristics and Response to AR101 PatientDisease Characteristics and Response to AR101 Subgroup Analysis PatientDisease Characteristics and Response to AR101 Discussion ID: 908523
Download Presentation The PPT/PDF document "Peanut Allergy Immunotherapy" is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Slide1
Peanut Allergy Immunotherapy
Slide2Slide3Peanut Allergy
Slide4Immunotherapy Options
Slide5Oral Immunotherapy
Slide6Patient/Disease Characteristics and Response to AR101
Slide7Patient/Disease Characteristics and Response to AR101: Subgroup Analysis
Slide8Patient/Disease Characteristics and Response to AR101: Discussion
Slide9QoL Improvements With AR101 Treatment Beyond the First Year (ARC004): Design
Slide10QoL Improvements With AR101 Treatment Beyond the First Year (ARC004): Demographics
Slide11QoL Improvements With AR101 Treatment Beyond the First Year (ARC004): Results
Slide12QoL Data in Clinical Practice
Slide13Real-World Survey, OIT for Food Allergy: Practice Patterns
Slide14Real-World Survey, OIT for Food Allergy: Practice Patterns (cont)
Slide15Real-World Survey, OIT for Food Allergy:
Side-Effect Management
Slide16Real-World Survey, OIT for Food Allergy:
Side-Effect Management (cont)
Slide17Real-World Survey, OIT for Food Allergy:
Side-Effect Management (cont)
Slide18Discussion: GI Side Effects
Slide19Epicutaneous Immunotherapy
Slide20REALISE (Real-Life Use and Safety of EPIT) Study
Background
Slide21REALISE Study Design and Safety Data Collection
Slide22REALISE Baseline Characteristics
Slide23REALISEBaseline Characteristics (cont)
Slide24REALISELocal Skin Reactions Over Time
Slide25REALISETreatment-Related TEAEs
Slide26REALISETreatment-Related Epinephrine Use
Slide27Long-Term Efficacy and Safety of EPIT (PEOPLE)
Study Design
Slide28PEOPLEChanges in ED Over 3 Years
Slide29PEOPLEChanges in Peanut IgG4 and IgE Levels
Slide30PEOPLESafety Data
Slide31Modeled Risk Reduction Through EPIT
Restaurant Meal Preparation
Slide32Modeled Risk Reduction Through EPIT
Predicted Absolute Risk (AR)
Slide33Modeled Risk Reduction Through EPIT
RRR at Month 12 DBPCFC
Slide34Food Contamination in Restaurants
Talking to Patients and Parents
Slide35Concluding Remarks
Slide36Conclusions: Oral Immunotherapy
Slide37Conclusions: Epicutaneous Immunotherapy
Slide38Abbreviations
Slide39Abbreviations (cont)